ES2101237T3 - Factor-4 plaquetario modificado. - Google Patents

Factor-4 plaquetario modificado.

Info

Publication number
ES2101237T3
ES2101237T3 ES93307592T ES93307592T ES2101237T3 ES 2101237 T3 ES2101237 T3 ES 2101237T3 ES 93307592 T ES93307592 T ES 93307592T ES 93307592 T ES93307592 T ES 93307592T ES 2101237 T3 ES2101237 T3 ES 2101237T3
Authority
ES
Spain
Prior art keywords
mpf
platelet factor
cpf
factor
potent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93307592T
Other languages
English (en)
Inventor
Shalley Kant Gupta
Jai Pal Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2101237T3 publication Critical patent/ES2101237T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/522Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA INVENCION SE BASA EN EL DESCUBRIMIENTO DE DOS FORMAS MODIFICADAS DEL FACTOR 4 DE LAS PLAQUETAS HUMANAS, AQUI LLAMADAS MPF-4 Y CPF-4, QUE FUERON AISLADAS A PARTIR DE UN MEDIO DE CULTIVO LIBRE DE SUERO DE LEUCOCITOS DE LA SANGRE PERIFERICO ESTIMULADOS CON LIPOPOLISACARIDOS. LA DETERMINACION DE LA SECUENCIA DE AMINOACIDO HA REVELADO QUE EL MPF-4 COMPARTE HOMOLOGIAS CON EL FACTOR 4 DE LAS PLAQUETAS COMENZANDO EN EL RESIDUO 17 N TERMINAL. EL CPF-4 CONSTA DE DISULFURO DE MPF-4 UNIDO A LOS 16 RESIDUOS N TERMINAL N DEL FACTOR 4 DE LAS PLAQUETAS. TANTO EL MPF-4 COMO EL CPF-4 SON POTENTES INHIBIDORES EN LA PROLIFERACION DE CELULAS ENDOTELIALES, ENTRE 10 Y 100 VECES MAS POTENTE QUE NATIVO O EL FACTOR 4 RECOMBINANTE DE LAS PLAQUETAS, HACIENDOLOS UTILES EN EL TRATAMIENTO DE ENFERMEDADES ANGIOGENICAS.
ES93307592T 1992-09-25 1993-09-24 Factor-4 plaquetario modificado. Expired - Lifetime ES2101237T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95279792A 1992-09-25 1992-09-25

Publications (1)

Publication Number Publication Date
ES2101237T3 true ES2101237T3 (es) 1997-07-01

Family

ID=25493243

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93307592T Expired - Lifetime ES2101237T3 (es) 1992-09-25 1993-09-24 Factor-4 plaquetario modificado.

Country Status (24)

Country Link
US (3) US5538949A (es)
EP (1) EP0589719B1 (es)
JP (1) JPH06220091A (es)
KR (1) KR940007059A (es)
CN (1) CN1035257C (es)
AT (1) ATE151777T1 (es)
AU (1) AU665114B2 (es)
BR (1) BR9303903A (es)
CA (1) CA2106629A1 (es)
CZ (1) CZ195193A3 (es)
DE (1) DE69309827T2 (es)
DK (1) DK0589719T3 (es)
ES (1) ES2101237T3 (es)
FI (1) FI934183A (es)
GR (1) GR3023356T3 (es)
HK (1) HK100597A (es)
HU (1) HUT69928A (es)
IL (1) IL107040A0 (es)
MX (1) MX9305901A (es)
MY (1) MY109158A (es)
NO (1) NO933423L (es)
NZ (1) NZ248724A (es)
YU (1) YU61893A (es)
ZA (1) ZA936925B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA936925B (en) * 1992-09-25 1995-03-20 Lilly Co Eli Modified platelet factor-4.
IL113561A0 (en) * 1994-05-09 1995-08-31 Lilly Co Eli Expression of recombinant mpf-4, cpf-4, pf-4 and precursor compounds
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
JPH09143199A (ja) * 1995-11-17 1997-06-03 Nippon Chem Res Kk 血小板第4因子の製造方法
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
FR2774990B1 (fr) * 1998-02-16 2000-07-28 Inst Vaisseaux Et Du Sang Nouveaux peptides, utilisation en therapeutique et compositions pharmaceutiques les renfermant
ES2431362T3 (es) 2001-09-12 2013-11-26 Sigma-Tau Research Switzerland S.A. Derivados de glicosaminoglicanos totalmente N-desulfatados como agentes inhibidores de la heparanasa, dotados con actividad antiangiogénica y desprovistos de efecto anticoagulante
EP1812468A2 (en) * 2004-09-15 2007-08-01 K.U.Leuven Research & Development Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
CN114805536B (zh) * 2022-06-24 2022-09-02 北京百臻生物技术有限公司 一种人血小板因子4蛋白突变体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US4737580A (en) * 1985-03-15 1988-04-12 Oncogen Platelet related growth regulator
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits
AU1539188A (en) * 1987-05-04 1988-11-10 Bristol-Myers Squibb Company TGF-B2 and novel compositions having anti-neoplastic activity
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5187075A (en) * 1989-01-26 1993-02-16 Sri International Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
EP0423641A3 (en) * 1989-10-18 1992-01-15 Nippon Mining Company Limited Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or tgfalpha
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
ZA936925B (en) * 1992-09-25 1995-03-20 Lilly Co Eli Modified platelet factor-4.

Also Published As

Publication number Publication date
YU61893A (sh) 1996-02-19
EP0589719B1 (en) 1997-04-16
AU4757393A (en) 1994-03-31
US5935928A (en) 1999-08-10
AU665114B2 (en) 1995-12-14
NO933423L (no) 1994-03-28
HU9302687D0 (en) 1993-12-28
IL107040A0 (en) 1993-12-28
GR3023356T3 (en) 1997-08-29
EP0589719A1 (en) 1994-03-30
DK0589719T3 (da) 1997-09-08
DE69309827T2 (de) 1997-08-28
HK100597A (en) 1997-08-08
JPH06220091A (ja) 1994-08-09
BR9303903A (pt) 1994-06-14
KR940007059A (ko) 1994-04-26
HUT69928A (en) 1995-09-28
CA2106629A1 (en) 1994-03-26
US5538949A (en) 1996-07-23
CN1035257C (zh) 1997-06-25
MX9305901A (es) 1994-05-31
ATE151777T1 (de) 1997-05-15
ZA936925B (en) 1995-03-20
CN1088216A (zh) 1994-06-22
DE69309827D1 (de) 1997-05-22
NZ248724A (en) 1995-10-26
FI934183A (fi) 1994-03-26
CZ195193A3 (en) 1994-04-13
NO933423D0 (no) 1993-09-24
MY109158A (en) 1996-12-31
US5512550A (en) 1996-04-30
FI934183A0 (fi) 1993-09-24

Similar Documents

Publication Publication Date Title
DE3876401D1 (de) N-terminale fragmente von menschlichem serumalbumin.
ATE110782T1 (de) Rekombinanter menschlicher endothelzellenwachstumsfaktor.
DE3856189D1 (de) Adhäsionsvarianten
DK455789D0 (da) Polypeptid
DE3770915D1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
DK0589719T3 (da) Modificeret blodpladefaktor-4
BR9007115A (pt) Novo trombolitico
EP0446315A4 (en) Recombinant product
ES2058479T3 (es) Compuestos peptidicos.
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
WO1995021916A3 (en) Pp32: a newly identified cd45-associated protein
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
RU93054511A (ru) Тромбоцитарные факторы, фармацевтическая композиция, способ получения тромбоцитарных факторов, днк, вектор, клетка
ATE335817T1 (de) Adhäsionsvarianten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 589719

Country of ref document: ES